Cocrystal(US:COCP)2025-11-14 13:00Antiviral Development - Cocrystal Pharma is focused on developing antiviral therapeutics for serious viral diseases, utilizing unique structure-based technologies[86]. - The influenza program includes CC-42344, which has shown in vitro efficacy against H5N1 avian influenza A strain with an EC50 of 0.003 µM[91]. - The Phase 2a study of oral CC-42344 demonstrated a favorable safety profile with no serious adverse events (SAEs) reported[93]. - Cocrystal is developing CDI-988 as a broad-spectrum antiviral for noroviruses and coronaviruses, with favorable safety results from Phase 1 studies[95][97]. - CDI-988's Phase 1 multiple-ascending dose (MAD) study showed that all doses from 100 mg to 1,200 mg were well tolerated[100]. - The company received FDA authorization for a Phase 1b challenge study of CDI-988, expected to begin in the first half of 2026[102]. - Cocrystal's HCV program targets the viral NS5B polymerase, aiming for ultra-short treatment regimens of four to six weeks[115]. - Cocrystal's influenza A/B program is material to the future development of a comprehensive antiviral program following the return of preclinical assets from Merck[94]. - The company continues to pursue novel antiviral compounds for coronavirus infections, targeting viral replication enzymes and protease[112]. Financial Performance - Total research and development expenses for the three months ended September 30, 2025, were $954,000, a decrease of $2,288,000 compared to $3,242,000 in 2024[120]. - Total research and development expenses for the nine months ended September 30, 2025, were $3,436,000, down from $10,500,000 in 2024, reflecting a decrease of $7,064,000[121]. - General and administrative expenses for the three months ended September 30, 2025, were $1,135,000, a decrease of $665,000 from $1,800,000 in 2024[123]. - General and administrative expenses for the nine months ended September 30, 2025, were $3,102,000, down from $4,148,000 in 2024, a decrease of $1,046,000[125]. - Net loss for the three months ended September 30, 2025, was $2,049,000, compared to a net loss of $4,939,000 in 2024[130]. - Net cash used in operating activities for the nine months ended September 30, 2025, was $6,456,000, a decrease from $13,325,000 in 2024[131]. - The Company had $7,729,000 in unrestricted cash on September 30, 2025, which is not sufficient to support its working capital needs for the next 12 months[134]. - The Company sold 2,764,710 shares of common stock at $1.70 per share in a registered direct offering on September 12, 2025[138]. - The Company has incurred operating losses and negative operating cash flows on an annual basis since inception[135]. Clinical Development - The Company is seeking a partner for further clinical development of CC-31244 after completing Phase 2a trials[117].